NO965591L - Combination treatment of HIV infection - Google Patents

Combination treatment of HIV infection

Info

Publication number
NO965591L
NO965591L NO965591A NO965591A NO965591L NO 965591 L NO965591 L NO 965591L NO 965591 A NO965591 A NO 965591A NO 965591 A NO965591 A NO 965591A NO 965591 L NO965591 L NO 965591L
Authority
NO
Norway
Prior art keywords
hiv infection
hiv
combination treatment
treatment
combination
Prior art date
Application number
NO965591A
Other languages
Norwegian (no)
Other versions
NO965591D0 (en
Inventor
Emilio A Emini
Joel R Huff
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO965591L publication Critical patent/NO965591L/en
Publication of NO965591D0 publication Critical patent/NO965591D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Blandingen av HIV-protease-inhibitoren, forbindelse J, og ett eller flere av nevarapin og et a-APA-derivat kan anvendes ved inhiberingen av HIV-protease, inhiberingen av HIV-reverstranskriptase, forhindringen eller behandlingen av infeksjon med HIV og behandlingen av AIDS, enten som for-bindelser, farmasøytisk akseptable sal-ter, bestanddeler i farmasøytisk pre-parat, enten i kombinasjon med eller ikke i kombinasjon med andre antivirus-midler, immunmodulatorer, antibiotika eller vaksiner. Fremgangsmåter for behandling av AIDS og fremgangsmåter for forhindring eller behandling av infeksjon med HIV er også beskrevet.The mixture of the HIV protease inhibitor, compound J, and one or more of nevarapine and an α-APA derivative may be used in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of HIV infection and the treatment of AIDS. , either as compounds, pharmaceutically acceptable salts, constituents of pharmaceutical preparations, whether in combination with or not in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating HIV infection are also described.

NO965591A 1994-06-27 1996-12-27 Combination treatment of HIV infection NO965591D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26708594A 1994-06-27 1994-06-27
PCT/US1995/007690 WO1996000068A2 (en) 1994-06-27 1995-06-23 Combination therapy for hiv infection

Publications (2)

Publication Number Publication Date
NO965591L true NO965591L (en) 1996-12-27
NO965591D0 NO965591D0 (en) 1996-12-27

Family

ID=23017251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965591A NO965591D0 (en) 1994-06-27 1996-12-27 Combination treatment of HIV infection

Country Status (14)

Country Link
EP (1) EP0767664A2 (en)
JP (1) JPH10503178A (en)
AU (1) AU2863895A (en)
CA (1) CA2193221A1 (en)
CZ (1) CZ375196A3 (en)
FI (1) FI965196L (en)
HU (1) HUT76546A (en)
IL (1) IL114208A0 (en)
MX (1) MX9700036A (en)
NO (1) NO965591D0 (en)
PL (1) PL317876A1 (en)
SK (1) SK163996A3 (en)
WO (1) WO1996000068A2 (en)
ZA (1) ZA955269B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
GB2324242A (en) * 1997-04-18 1998-10-21 Atindra Nath Chakrabarty Medicaments for treating viral infections
CA2384188C (en) 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
JP6936229B2 (en) 2015-09-23 2021-09-15 マルバーン パナリティカル リミテッド Particle characterization

Also Published As

Publication number Publication date
FI965196A7 (en) 1996-12-23
ZA955269B (en) 1996-02-02
CA2193221A1 (en) 1996-01-04
HUT76546A (en) 1997-09-29
WO1996000068A2 (en) 1996-01-04
CZ375196A3 (en) 1997-07-16
HU9603567D0 (en) 1997-02-28
JPH10503178A (en) 1998-03-24
MX9700036A (en) 1997-04-30
FI965196A0 (en) 1996-12-23
IL114208A0 (en) 1995-10-31
PL317876A1 (en) 1997-04-28
SK163996A3 (en) 1997-08-06
FI965196L (en) 1996-12-23
NO965591D0 (en) 1996-12-27
AU2863895A (en) 1996-01-19
EP0767664A2 (en) 1997-04-16
WO1996000068A3 (en) 1996-02-22

Similar Documents

Publication Publication Date Title
DE60036961D1 (en) GAMMA-HYDROXY-2- (FLUORALKYLAMINOCARBONYL) -1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR
ATE175412T1 (en) HIV PROTEASE INHIBITORS
MY109834A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
NO953308L (en) Inhibitors of HIV reverse transcriptase
EA200400585A1 (en) N-SUBSTITUTED HYDROXYPYRIMIDINON-CARBOXAMIDE HIV INHIBITORS INTEGRASES
ATE252081T1 (en) NEW HIV PROTEASE INHIBITORS
BR9711095A (en) Substituted cyclopentane compound, composition and method for inhibiting influenza virus neuraminidase and method for treating influenza virus infection
NO953876L (en) HIV protease inhibitors useful for the treatment of AIDS
ATE215952T1 (en) HIV PROTEASE INHIBITORS
NO962000L (en) Promoters of an HIV protease inhibitor
ZA991029B (en) Composition and methods for treatment of hiv infections.
NO965591L (en) Combination treatment of HIV infection
EA199700150A1 (en) COMBINED TREATMENT WITH RESPECT OF HIV INFECTION USING HIV PROTASE INHIBITOR INDINAVIAR AND REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, ddI OR ddC
NO20002481L (en) Combination therapy for the treatment of AIDS
HK1041444A1 (en) Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
DE69529678D1 (en) COMBINATIONS OF HIV PROTEASE INHIBITORS
FI970565A0 (en) HIV proteasinhibitorkombination
NO944208L (en) Novel quinazolines as inhibitors of HIV reverse transcriptase
KR970703770A (en) Combination therapy for HIV infection